Carlsmed Names ZimVie CFO Richard Heppenstall to Lead Finance Amid Growth Push
Event summary
- Richard Heppenstall appointed CFO of Carlsmed, effective immediately, succeeding Leo Greenstein.
- Heppenstall brings 30 years of experience in healthcare, life sciences, and technology, most recently as CFO of ZimVie Inc.
- Carlsmed reaffirms full-year 2026 revenue guidance of $74–$78 million, representing 50% growth over 2025.
- New aprevo® Lumbar spinal fusion procedure CMS reimbursement begins October 1, 2026.
- Upcoming launches of aprevo® Lumbar Bi-lateral and corra™ cervical procedures.
The big picture
Carlsmed's appointment of Richard Heppenstall as CFO underscores its focus on scaling operations amid a wave of product launches and reimbursement changes. The move comes as the company targets 50% revenue growth in 2026, positioning itself in the competitive AI-enabled spine surgery market. Heppenstall's background in orthopedic and tech finance suggests a strategic emphasis on operational efficiency and disciplined execution.
What we're watching
- Execution Risk
- Whether Carlsmed can scale operations and launch new procedures while maintaining financial discipline.
- Reimbursement Impact
- How the new CMS reimbursement policy will affect adoption of the aprevo® Lumbar procedure.
- Leadership Transition
- How Heppenstall's strategic and operational expertise will influence Carlsmed's growth trajectory.